| Date | Title | Description |
| 05.11.2024 | Sobi's New Leadership: A Strategic Shift in the Biopharmaceutical Landscape | In the ever-evolving world of biopharmaceuticals, leadership changes can signal new directions and strategies. Recently, Swedish Orphan Biovitrum AB (Sobi) announced the nomination of David Meek as the new Chair of the Board of Directors. T... |
| 05.11.2024 | Navigating the Waters of Biotech and Pharma: A Tale of Leadership and Growth | In the ever-evolving landscape of biotechnology and pharmaceuticals, leadership is the compass guiding companies through turbulent waters. Recent developments at Senhwa Biosciences and Novartis illustrate this dynamic vividly. Each company ... |
| 05.11.2024 | Navigating Change in Biopharma: Leadership Shifts at Senhwa and Sobi | The biopharmaceutical landscape is a dynamic arena, where leadership changes can signal new directions and strategies. Recently, two companies, Senhwa Biosciences and Swedish Orphan Biovitrum AB (Sobi), have made significant appointments th... |
| 04.11.2024 | David Meek is proposed as new Chair of the Board of Directors of Sobi | David Meek is proposed as new Chair of the Board of Directors of Sobi
Mon, Nov 04, 2024 21:00 CET Report this content
The Nomination Committee of Swedish Orphan Biovitrum AB (publ) (Sobi®) proposes that David Meek is elected as new Chair of... |
| 02.11.2024 | Novartis CEO 'very confident' on sales target, doesn't fear patent cliff - newspaper | Healthcare & PharmaceuticalsCommercial Strategy
Novartis CEO 'very confident' on sales target, doesn't fear patent cliff - newspaper
By ReutersNovember 2, 20249:39 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Faceboo... |
| 01.11.2024 | Senhwa Biosciences Announces the Appointment of Dr. Yiu-Lian Fong, the Former Global Head of Janssen Diagnostic Innovation and R&D at Johnson & Johnson as the New Corporate Director | TAIPEI and SAN DIEGO, Nov. 1, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced the appointme... |
| 29.10.2024 | Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile | Ad hoc announcement pursuant to Art. 53 LR
Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III trial vs. all standard of care (SoC) therapies... |
| 29.10.2024 | Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance | Ad hoc announcement pursuant to Art. 53 LRQ3 net sales grew +10% (cc1, +9% USD) with core operating income up +20% (cc, +17% USD) Sales growth driven by continued strong performance from Entresto (+26% cc), Cosentyx (+28% cc), Kisqali (+43%... |
| 28.10.2024 | Monte-Rosa Therapeutics enters billion-dollar partnership with Novartis |
Monte Rosa Therapeutics is a clinical-stage biotechnology company based in Boston and Basel developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune ... |
| 26.10.2024 | Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial | New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1
Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate (eGFR) slope – a key measure of kidney function – vs. patients’ historic ... |
| 24.10.2024 | Fortune Global Forum Speaker Lineup Unveiled for Nov. 11-12 in New York City | Seven-Time World Champion and Entrepreneur Tom Brady and Deputy Managing Director of the IMF Gita Gopinath among other luminaries confirmed to speak at Fortune's annual gathering of top global business executives and policy leaders
Leon Pan... |
| 18.10.2024 | The Microbiome Revolution: Holobiome's $9 Million Leap Forward | In the world of health and wellness, the gut is the new frontier. Holobiome, a microbiome platform company, has just secured $9 million in a Seed funding round. This investment is not just a financial boost; it’s a signal that the microbiom... |
| 18.10.2024 | Consumer groups ask FTC to block Novo Holdings-Catalent deal | Boards, Policy & RegulationMergers & Acquisitions
Regulatory Oversight
Corporate Counsel
Health
Consumer groups ask FTC to block Novo Holdings-Catalent deal
By Jody Godoy and Maggie FickOctober 17, 20249:55 PM UTCUpdated ago
Text
Sm... |
| 18.10.2024 | Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer | If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment with Kisqali® (ribociclib) in combinati... |
| 17.10.2024 | Mars Petcare's Leadership Shake-Up: A New Era for Veterinary Health and Diagnostics | In a bold move, Mars Petcare has reshuffled its leadership deck, signaling a fresh chapter for its Veterinary Health and Science & Diagnostics divisions. This change comes as the company, a titan in the pet care industry, seeks to innov... |
| 16.10.2024 | The Rise of Influencer Marketing in Healthcare: A New Era of Patient Engagement | In the world of healthcare, change is the only constant. The latest shift? Influencer marketing. It’s not just a trend; it’s a revolution. Havas Lynx has stepped into the spotlight with a bold new offering that taps into the power of influe... |
| 16.10.2024 | USD 8M and a strategic partner for Ikerian AG |
Ikerian AG and its subsidiary, RetinAI U.S. Inc. are committed to revolutionizing the way ophthalmology clinics connect and manage patient data. Established in 2017, the company develops software solutions to accelerate clinical, research ... |
| 16.10.2024 | Ikerian Holds Series B Funding First Close of USD 8M | (left) Carlos Ciller, PhD, CEO, co-founder and Chairman Ikerian AG and RetinAI US Inc.; (center) Stefanos Apostolopoulos, PhD, CTO and co-founder Ikerian AG and RetinAI US Inc.; (right) Sandro De Zanet, PhD, Chief Scientific Officer and co-... |
| 15.10.2024 | USV launches its version of heart-failure drug | Drugmaker USV has introduced OnArni, a fixed dose combination of Sacubitril and Valsartan, for the management of heart failure, priced at ₹8 for a 50 mg tablet.
This addresses the rising cases of heart failure in India, the company said, po... |
| 14.10.2024 | Havas Lynx Launches Global Healthcare Influencer Offering | Havas Lynx announced today the launch of a new global healthcare influencer offering that leverages the power of influencers to drive health outcomes and behaviour change. Havas Lynx’s Dr. Tapas Mukherjee, Medical Director, and Matt Eagles,... |
| 08.10.2024 | Generare raises €5M to scale the discovery of new medicines and molecules hiding in microbes | Generare, a biotech uncovering the next generation of medicines and high-value molecules hiding in soil bacteria, has raised €5M in Seed funding from Teampact.ventures, Galion.Exe and EU-backed VIVES Partners, to bring its “discovery factor... |
| 08.10.2024 | Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy | MELBOURNE, Australia, Oct. 8, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Australian Therapeutic Goods Administration (TGA) has approved the use of Illuccix® (kit for the prepar... |
| 04.10.2024 | Frazier Life Sciences: Over $630 Million Added To Evergreen Public Fund | Frazier Life Sciences (FLS), a healthcare investment firm focused on innovative therapeutics, announced it has closed on over $630 million in capital commitments to its evergreen Public Fund from new and existing investors in an oversubscri... |
| 04.10.2024 | Jeff Zevely to emcee the 2024 San Diego Miles for Melanoma 5K | Jeff Zevely
The Melanoma Research Foundation (MRF) is thrilled to announce that Jeff Zevely will be returning to emcee the annual Miles for Melanoma San Diego 5K event on Sunday, October 20, 2024 at De Anza Cove Park. Jeff will welcome gues... |
| 25.09.2024 | Synple chem joins US-based eMolecules |
Founded by Benedikt Wanner (Founder & CEO) AND Paula Nichols (Co-founder and CCO) along with their team, Synpl Chem is a pioneering Zurich-based company that specializes in automated chemical synthesis for small molecules drug discover... |
| 20.09.2024 | Family Heart Foundation Launches AI Model for Early Cardiovascular Disease Detection | What You Should Know:
– The Family Heart Foundation, a leader in cardiovascular research and advocacy, has unveiled an “FIND Lp(a)” a machine learning model to combat premature heart disease and stroke. The first-of-its-kind offering is set... |
| 19.09.2024 | A New Dawn in Kidney Cancer Treatment: Roswell Park's Breakthrough Regimen | In the realm of cancer treatment, hope often flickers like a candle in the dark. But recent findings from Roswell Park Comprehensive Cancer Center have ignited a brighter flame for patients battling metastatic kidney cancer. At the European... |
| 19.09.2024 | Радиофармацевтические препараты назвали прорывом в борьбе с раком | Производители лекарств делают ставку на то, что доставка радиации непосредственно к опухолям станет следующим большим прорывом в борьбе с раком. Bristol Myers Squibb, AstraZeneca, Eli Lilly и другие фармацевтические компании потратили около... |
| 18.09.2024 | Tech Park Basel zieht Bilanz |
Der Tech Park Basel ist seit Sommer 2011 in Betrieb. Neben den auf die Nutzung durch junge Technologieunternehmen zugeschnittenen Büro- und Laborflächen stellt der Tech Park Basel auch verschiedene Infrastrukturen bereit und bietet Dienstl... |
| 17.09.2024 | FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer | Ad hoc announcement pursuant to Art. 53 LR
Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy1,2
Kisqali® (ribo... |
| 16.09.2024 | ONL Therapeutics Closes $65M Series D Financing | ONL Therapeutics, an Ann Arbor, MI-based clinical-stage biopharmaceutical company focused on advancing treatments of geographic atrophy (GA) associated with dry age-related macular degeneration (AMD), raised $65M in Series D funding.
The ro... |
| 15.09.2024 | Roswell Park-Designed Treatment Regimen Doubles Progression-Free Survival in Metastatic Kidney Cancer | Roswell Park's Saby George, MD, presented study findings highlighting a treatment combination shown to extend survival in patients with advanced kidney cancer.
During the European Society for Medical Oncology (ESMO) Congress, Saby George, M... |
| 12.09.2024 | The Hidden Struggles of X-Linked Hypophosphatemia: A Call for Awareness and Action | X-linked hypophosphatemia (XLH) is a name that may not ring a bell for many. Yet, for those affected, it’s a daily battle. A recent analysis from the XLH Disease Monitoring Program (DMP) sheds light on the harsh realities faced by adults li... |
| 11.09.2024 | Y Combinator-backed Cerrion raises $5 million in funding to boost AI Video tech in manufacturing | Zurich video AI startup Cerrion has raised $5 million in funding.
The round was led by Y Combinator and Justin Kan’s Goat Capital, with additional participation from session.vc, Soma Capital, 10x Founders, Rebel Fund and renowned angel inve... |
| 10.09.2024 | Cerrion: The Dawn of AI in Manufacturing Automation | In the world of manufacturing, time is money. Every second lost to inefficiency can cost companies dearly. Enter Cerrion, a Zurich-based start-up that is reshaping the landscape of industrial automation. With a fresh infusion of $5 million ... |
| 10.09.2024 | Epsilogen Secures £12.5 Million to Propel Cancer Treatment Innovations | Epsilogen, a pioneering force in the realm of immunoglobulin E (IgE) antibodies, has successfully raised £12.5 million in a Series B funding round. This brings the total Series B financing to an impressive £43.25 million. The funds will be ... |
| 10.09.2024 | Great Lakes Institute of Management, Gurgaon, Conducts its 13th Annual Convocation | Delhi, India
Great Lakes Institute of Management, Gurgaon conducted its 13th Annual Convocation on 24th August 2024 at the Manekshaw Centre Auditorium, New Delhi. A total of 342 students successfully graduated on this day from two programs:... |
| 10.09.2024 | AI-powered automation start-up Cerrion raises USD 5 million |
By automating tasks traditionally handled by skilled operators, Cerrion’s AI video-led technology helps manufacturers maintain productivity despite workforce shortages. It leverages standard CCTV cameras to learn and monitor production pro... |
| 09.09.2024 | Epsilogen: Immunoglobulin Development Company Raises £12.5 Million (Series B) | Epsilogen – a leader in the development of immunoglobulin E (IgE) antibodies to treat cancer – announced today the completion of a £12.5 million Series B expansion financing, bringing the Series B total to £43.25 million. The funding will a... |
| 09.09.2024 | More space for healthtech start-ups on the Novartis Campus |
Digitalisation is one of the megatrends in the healthcare sector. It not only promises greater efficiency, but also new possibilities in diagnostics and therapeutics. As this field requires expertise that traditional healthcare companies o... |
| 05.09.2024 | Novartis Expands Radioligand Therapy Manufacturing in the U.S. | In a bold move to combat cancer, Novartis is laying the groundwork for two new radioligand therapy (RLT) manufacturing facilities in the United States. This expansion is not just a step; it’s a leap into the future of cancer treatment. With... |
| 05.09.2024 | Raising Awareness and Empowering Patients: The Fight Against Kidney Disease | Kidney disease is a silent predator. It lurks in the shadows, often unnoticed until it strikes. The statistics are alarming. Approximately 35.5 million adults in the U.S. have chronic kidney disease (CKD), yet around 90% are unaware of thei... |
| 04.09.2024 | The NKF Launches New Online Educational Tool for People Living with Chronic Kidney Disease | ~NKF Patient Journey: Chronic Kidney Disease Offers An Individualized Educational Curriculum~
NEW YORK, Sept. 4, 2024 /PRNewswire/ -- Today, the National Kidney Foundation (NKF) launched NKF Patient Journey: Chronic Kidney Disease, a new in... |
| 04.09.2024 | Ian Michael Crumm to emcee the 2024 New York Miles for Melanoma 5K | Ian Michael Crumm, 2024 New York Miles for Melanoma 5K event emcee
The Melanoma Research Foundation (MRF) is thrilled to announce the next event in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patien... |
| 04.09.2024 | Novartis begins construction of two new radioligand therapy facilities in the US, expanding its world-class RLT manufacturing and supply network | Indianapolis site expansion will establish in-house production of isotopes critical for production of radioligand therapies (RLTs) for cancer treatment
New facility in California will be third US-based RLT production facility
Novartis is ex... |
| 03.09.2024 | General Anesthesia Drugs Market: Trends, Segmentation, and Future Outlook | Share
Tweet
Share
Share
Email
The global general anesthesia drugs market has been experiencing significant evolution, driven by advancements in medical technology, increasing surgical procedures, and a growing emphasis on patient safety and... |
| 03.09.2024 | Pharmaceutical Market: Trends, Segmentation, and Growth Opportunities | Share
Tweet
Share
Share
Email
In recent years, the pharmaceutical market has witnessed remarkable growth and transformation, driven by technological advancements, evolving consumer needs, and the global push for better healthcare solutions.... |
| 03.09.2024 | NephCure Announces First-Ever IgA Nephropathy (IgAN) Awareness Day on September 26, 2024 | PHILADELPHIA, Sept. 3, 2024 /PRNewswire/ -- NephCure, a leading nonprofit organization dedicated to finding better treatments and a cure for rare kidney disease, is proud to announce the inaugural IgA Nephropathy (IgAN) Awareness Day on Sep... |
| 03.09.2024 | Parkinson’s Disease Drug Market: Trends, Growth, and Segmentation | Share
Tweet
Share
Share
Email
Parkinson’s disease, a progressive neurodegenerative disorder characterized by motor symptoms such as tremors, rigidity, and bradykinesia, affects millions of individuals worldwide. As the global population age... |
| 03.09.2024 | SKIES ACROSS NORTH AMERICA TO LIGHT UP THIS FALL IN SUPPORT OF BLOOD CANCER PATIENTS | The Leukemia & Lymphoma Society kicks off philanthropic campaign Light The Night; communities nationwide encouraged to learn why awareness and support is critical
RYE BROOK, N.Y., Sept. 3, 2024 /PRNewswire/ -- The Leukemia & Lymphom... |
| 29.08.2024 | Navigating the New Normal: COVID Vaccines and Creative Leadership in Healthcare | The landscape of healthcare marketing is shifting. Imre, a prominent brand engagement agency, has made significant strides by appointing Tracy Zuto and Malia Baker as key creative leaders. Their arrival signals a commitment to innovative, i... |
| 28.08.2024 | Imre announced two new appointments to Strengthen Brand AOR Expertise | Imre continues its commitment to cutting-edge creative that builds brand engagement with the appointment of two senior creative leaders, as the agency strengthens its position as a distinct choice for agency-of-record assignments in healthc... |
| 27.08.2024 | Imre Appoints Powerhouse Leaders Tracy Zuto and Malia Baker and Strengthens Brand AOR Expertise | New Additions Reflect Commitment to Creative Excellence and Healthcare Industry Leadership
NEW YORK, Aug. 27, 2024 /PRNewswire/ -- Imre continues its commitment to cutting-edge creative that builds brand engagement with the appointment of t... |
| 26.08.2024 | Opna Bio Doses First Patient in Phase 1 Study in Multiple Myeloma with OPN-6602, an EP300/CBP Bromodomain Inhibitor | Appoints Axel Bolte, MBA, MSc, to Board Director and Stephanie Oestreich, PhD, MPA, to Board Observer
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–August 26, 2024–
Opna Bio announced that it has dosed the first patient with OPN-6602, a poten... |
| 24.08.2024 | The Rise of RNA Medicines: Borealis Biosciences and the Future of Kidney Disease Treatment | In the world of biotechnology, innovation is the lifeblood. Borealis Biosciences has emerged as a beacon of hope in the treatment of kidney diseases. Recently, the company raised $150 million in Series A financing, marking a significant mil... |
| 22.08.2024 | Novartis, Versant hope to repeat Chinook’s success by arming kidney biotech Borealis with $150M | Novartis’ $3.2 billion deal for Chinook Therapeutics gave the Swiss Big Pharma such a taste for kidney disease-focused biotechs that it has partnered with VC firm Versant Ventures to create another company in a similar mold.
Borealis Biosci... |
| 22.08.2024 | Trinity Life Sciences Announces New Customer Engagement Solutions | Trinity Life Sciences, the leader in strategy, insights and analytics for the life sciences industry, announces new Customer Engagement solutions leveraging both Trinity’s deep commercial insight and recognized technology platform. The new ... |
| 22.08.2024 | Global Genes' Annual Week in RARE Event Heading to Kansas City | Global Genes
Global Genes is taking Week In RARE on the road to Kansas City, after having hosted this annual event in California for over 12 years. Moving the location annually will help make the event more accessible and equitable to the g... |
| 22.08.2024 | Borealis Biosciences: RNA Medicines Company Raises $150 Million (Series A) | Borealis Biosciences, a next-generation RNA medicines company, has emerged from stealth with $150 million in combined Series A financing from founding investor Versant Ventures and Novartis, and committed strategic research collaboration fu... |
| 21.08.2024 | Glenmark and SalioGen: A New Era in Ophthalmic Treatments | In the bustling world of pharmaceuticals and biotechnology, two companies are making waves in the ophthalmic sector. Glenmark Therapeutics Inc. and SalioGen Therapeutics are not just players; they are pioneers. Their recent announcements re... |
| 21.08.2024 | Innovations in Financial Planning: A New Era for Later Life Management | In the world of finance, innovation is the lifeblood that keeps the industry vibrant. Recently, two companies emerged as champions in the Later Life Financial Planning Innovation Challenge, hosted by Smart Data Foundry and FinTech Scotland.... |
| 20.08.2024 | REPUBLICA HAVAS EXPANDS NORTH AMERICAN FOOTPRINT WITH THREE APPOINTMENTS | A trio of executives has been appointed to lead the agency's expansion into New York City
NEW YORK, Aug. 20, 2024 /PRNewswire/ - Republica Havas announced today the appointments of three executives to lead the agency's continued expansion i... |
| 19.08.2024 | Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC) | MAHWAH, N.J., Aug. 19, 2024 /PRNewswire/ -- Glenmark Therapeutics Inc., USA (Glenmark) is pleased to announce it has launched1 Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC); compare to the active ingredient in Pataday®2 Twic... |
| 19.08.2024 | SalioGen Therapeutics Appoints Kali Stasi, M.D., Ph.D. as Chief Medical Officer | -Dr. Stasi brings to SalioGen 30 years of experience in ophthalmology and genetic medicine-
LEXINGTON, Mass., Aug. 19, 2024 /PRNewswire/ -- SalioGen Therapeutics, a biotechnology company developing next-generation genetic medicines based on... |
| 17.08.2024 | KNIME: Open-Source Data Science And AI Company Raises $30 Million | KNIME, one of the leading open-source data science and AI companies, announced it has raised additional funding from its longstanding investor, Invus. Since the last announcement, Invus has invested another $30 million, bringing the total f... |
| 15.08.2024 | Invus invests additional $30M in Knime |
KNIME helps everybody make sense of data. Its free and open-source KNIME Analytics Platform enables anyone – from business to technical and data backgrounds – to intuitively work with data. KNIME Hub is the commercial complement to KNIME A... |
| 09.08.2024 | GenScript Biotech Reports First Half 2024 Results | Strong Revenue Growth and Strategic Advances Across Key Segments, Enhances Commitment to ESG and Sustainable Development
Impressive Financial Growth: The group reported a 43.5% increase in revenue, driven by a 156% boost in cell therapy rev... |
| 08.08.2024 | Gilead quarterly profit beats Street estimates, revenue up 5% | Healthcare & PharmaceuticalsCommercial Strategy
Gilead quarterly profit beats Street estimates, revenue up 5%
By Deena BeasleyAugust 8, 20248:05 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Li... |
| 08.08.2024 | Novartis Pharma K.K. Novartis achieved significant sales growth and improved core operating profit margin in the second quarter; upwardly revised full-year 2024 core operating profit forecast | - |
| 08.08.2024 | Novartis Pharma K.K. Novartis achieved significant sales growth and improved core operating profit margin in the second quarter; upwardly revised full-year 2024 core operating profit forecast | Novartis Pharma K.K.
Novartis achieved strong sales growth and improved core operating profit margin in the second quarter; revised full-year 2024 core operating profit forecast upward
……
This material is a Japanese translation (summary) of... |
| 07.08.2024 | KNIME's Bold Leap into the Future of AI Governance | In the fast-paced world of artificial intelligence, the race is on. Companies are scrambling to harness the power of AI while managing its risks. KNIME, a leader in open-source data science, has just made a significant move. The company sec... |
| 07.08.2024 | Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN) | Ad hoc announcement pursuant to Art. 53 LR
Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs. ... |
| 07.08.2024 | Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN) | Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs. placebo (p |
| 06.08.2024 | KNIME Secures Investment to Accelerate Enterprise AI Governance and ModelOps | KNIME, one of the leading open-source data science and AI companies, has raised additional funding from its longstanding investor Invus. Since the last announcement, Invus invested another $30M, bringing total funding to $50M. This will all... |
| 06.08.2024 | Open-source data science platform Knime raises $30M to seize opportunity in generative AI
Your vote of support is important to us and it helps us keep the content FREE.
One click below supports our mi... | Open-source data science platform provider Knime AG said today it has closed on a new, $30 million investment from its longtime backer Invus.
The round is the first major investment the company has received since Invus led its initial Serie... |
| 05.08.2024 | QBIOTICS WELCOMES STEPHEN DOYLE AS CHIEF EXECUTIVE OFFICER | Stephen Doyle has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and Boehringer Ingelheim. He was most recently Chief Business Officer at Aslan Ph... |
| 05.08.2024 | QBIOTICS WELCOMES STEPHEN DOYLE AS CHIEF EXECUTIVE OFFICER | Stephen Doyle has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and Boehringer Ingelheim. He was most recently Chief Business Officer at Aslan Ph... |
| 01.08.2024 | Shanghai to ramp up support for cutting-edge biomedical tech | Lujiazui, the financial center in Shanghai, forms a perfect backdrop to the Bund area. [Wang Gang/For China Daily]
Shanghai will strengthen efforts to develop cutting-edge biomedical technologies, such as gene and cell therapies, mRNA, synt... |
| 27.07.2024 | The Shifting Landscape of Biopharma and Real Estate in Colorado | In the heart of Colorado, two significant developments are reshaping the landscape of biopharmaceuticals and commercial real estate. The recent acquisition of a former Mile High Labs site by ScanlanKemperBard (SKB) and a strategic collabora... |
| 27.07.2024 | The Future of Brain Health: Innovations and Leadership in Alzheimer's and Multiple Sclerosis Treatments | In the ever-evolving landscape of biotechnology, two companies are making waves in the treatment of chronic neurological diseases: Immunic, Inc. and Neurophet. Both are leveraging advanced technologies and seasoned leadership to tackle the ... |
| 25.07.2024 | A Race Against Melanoma: Cleveland's Miles for Melanoma 5K**
** | ** On a sunny August morning, the air buzzes with anticipation. The Cleveland Miles for Melanoma 5K is set to unfold at Edgewater Park. This event is more than just a race; it’s a lifeline. It brings together a community united by a common ... |
| 25.07.2024 | The Rising Tide of Myopia: A Call to Action for Parents and Communities**
** | ** In a world increasingly dominated by screens, the vision of our children hangs in the balance. Myopia, or nearsightedness, is not just a minor inconvenience; it’s a growing epidemic. The statistics are staggering. In Singapore, 65% of ch... |
| 24.07.2024 | Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec | – Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience –
– Served as Neuroimmunology Franchise Head Responsible for Roche's Blockbuster Launch of Multiple Sclerosis Therapy Ocrevu... |
| 24.07.2024 | Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer | – Collaboration combines Dren’s targeted cell depletion platform with Novartis research, development and commercial expertise to advance innovative therapies for cancer –
– Dren Bio to receive total upfront consideration of $150 million and... |
| 24.07.2024 | Business | ScanlanKemperBard buys former Sandoz, Mile High Labs site in Broomfield | Novartis cited double-digit price erosion from consolidation and increased competition in the U.S. generic drug market as reasons for the closure.
Originally based in Longmont when it was founded in 2016, Mile High Labs moved production to ... |
| 19.07.2024 | The Melanoma Research Foundation to host the Cleveland Miles for Melanoma 5K | Apex Skin
The Melanoma Research Foundation (MRF) is thrilled to announce one of the next events in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, supporters, care partners and thrivers. This ... |
| 18.07.2024 | Novartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance | Ad hoc announcement pursuant to Art. 53 LRQ2 net sales grew +11% (cc1, +9% USD) with core operating income up +19% (cc, +17% USD) Sales growth driven by continued strong performance from Entresto (+28% cc), Kesimpta (+65% cc), Cosentyx (+22... |
| 10.07.2024 | Azzur Group Appoints Two New Laboratory Directors | HATBORO, Pa., July 10, 2024 /PRNewswire/ -- Azzur Group today announces the appointment of new leadership for its cGMP microbiology and analytical laboratories. Joy Ghosh, PhD, has been named Senior Director, Laboratory Services in Schnecks... |
| 09.07.2024 | The 5G Revolution: Transforming Healthcare and Smartphone Markets | A deep dive into the impact of 5G technology on healthcare services and smartphone markets, highlighting the growth of MediaTek in the 5G smartphone sector and the potential of 5G in revolutionizing patient care and remote medicine.
5G Tech... |
| 08.07.2024 | BioCity announces its endothelin receptor A selective antagonist SC0062 met the primary endpoint in IgA nephropathy in 2-SUCCEED trial: a randomized, double-blind, placebo-controlled Phase 2 trial | SHANGHAI, July 8, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 met the primary endpoint of proteinuria reduction in the 2-SUCCEED trial: a randomized, double-bli... |
| 07.07.2024 | Hainan Free Trade Port deepens cooperation with Switzerland | HAIKOU, China, July 7, 2024 /PRNewswire/ -- A report from Hainan International Media Center (HIMC):
On July 4, the Hainan Free Trade Port Medical & Health Industry Exchange Meeting was held in Zurich, Switzerland.
From July 4-6, a deleg... |
| 06.07.2024 | 5G Technology: Revolutionizing Healthcare and Remote Medicine | Share
Tweet
Share
Share
Email
The advent of 5G technology marks a new era in the field of telecommunications. While its potential is vast across various sectors, one of the most transformative impacts of 5G is seen in healthcare and remote ... |
| 01.07.2024 | Inaugural European entrepreneur award crowns HAYA Therapeutics Founders |
Recognizing entrepreneurial vision and talent in the life sciences among the DACH region, which includes Germany, Austria and Switzerland, the award honors the efforts of Drs. Ounzain and Blessing in creating a company developing an innova... |
| 28.06.2024 | PepTalkHer Buys Mettacool | Mettacool Co-CEOs Molly Dewey (L) and Natalie Eicher (R) with Meggie Palmer, CEO and Co-Founder, PepTalkHer (Center)
PepTalkHer, an executive coaching platform and app dedicated to fostering professional growth and equitable pay, acquired l... |
| 21.06.2024 | Envision Energy's Path to Net Zero: A Green Revolution Unveiled | Envision Energy, a global leader in green technology, has unveiled its 2024 Net Zero Action Report at Intersolar in Munich, showcasing its remarkable achievements in global decarbonization. This report marks the company's second consecutive... |
| 21.06.2024 | Envision Energy Releases 2024 Net Zero Action Report Highlighting Global Decarbonization Achievements | MUNICH, June 21, 2024 /PRNewswire/ -- Envision Energy, a global leader in green technology, has unveiled its 2024 Net Zero Action Report at Intersolar in Munich. This report highlights the company's ongoing decarbonization achievements, mar... |
| 20.06.2024 | Envision Energy Releases 2024 Net Zero Action Report Highlighting Global Decarbonization Achievements | MUNICH, June 20, 2024 /PRNewswire/ -- Envision Energy, a global leader in green technology, has unveiled its 2024 Net Zero Action Report in Intersolar, declaring its second consecutive year of carbon-neutral operations on a global scale. Th... |
| 19.06.2024 | CMT Research Foundation Invests in ReviR Therapeutics Research to Pioneer Small Molecule Therapeutics for CMT1A | ATLANTA, June 19, 2024 /PRNewswire/ -- The CMT Research Foundation, a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease (CMT)*, has formed a strategic partnership with ReviR Therapeutics to advance... |
| 18.06.2024 | Learn To Win: Enterprise SaaS Training Company Raises $30 Million | Learn to Win, a leading provider of personalized, predictive, and secure enterprise training software, announced it has raised an oversubscribed $30 million in Series A funding led by the Westly Group, with follow-on participation from Norw... |
| 18.06.2024 | Выдающийся врач-онколог Павел Борисович Попов: от детских экспериментов до мировой славы | - |
